Bladder Cancer
Omega-3, omega-6 fatty acids may protect against several cancers
Higher omega-3 and omega-6 fatty acid levels may help reduce cancer risk, according to study findings.
Gilead to withdraw Trodelvy accelerated approval for bladder cancer
Gilead Sciences announced its intention to voluntarily withdraw the accelerated approval for sacituzumab govitecan-hziv for treatment of certain patients with advanced bladder cancer.
Novel drug delivery approach may protect against cisplatin-related hearing loss
A novel drug delivery construct may protect individuals against cisplatin-induced ototoxicity and associated hearing loss.
MS linked to greater risk for certain cancers
People with MS had an increased risk for bladder, brain and cervical cancers compared with people without MS, according to a new study in Neurology, the medical journal of the American Academy of Neurology.
Extended lymphadenectomy does not improve bladder cancer outcomes, increases morbidity
Extended lymphadenectomy offered no survival benefit for patients with localized muscle-invasive bladder cancer compared with bilateral standard lymphadenectomy for patients undergoing radical cystectomy, according to study findings.
Durvalumab regimen improves outcomes in muscle-invasive bladder cancer
Use of durvalumab before and after radical cystectomy improved outcomes for patients with muscle-invasive bladder cancer, according to results of the randomized phase 3 NIAGARA trial.
Urothelial Bladder Cancer
Urothelial Bladder Cancer
Durvalumab regimen improves survival in muscle-invasive bladder cancer
The combination of durvalumab and chemotherapy improved outcomes compared with neoadjuvant chemotherapy alone for patients with muscle-invasive bladder cancer, according to the agent’s manufacturer.